Cargando…

Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation

Introduction: Tacrolimus is the backbone immunosuppressant after solid organ transplantation. Tacrolimus has a narrow therapeutic window with large intra- and inter-patient pharmacokinetic variability leading to frequent over- and under-immunosuppression. While routine therapeutic drug monitoring (T...

Descripción completa

Detalles Bibliográficos
Autores principales: Fontova, Pere, Colom, Helena, Rigo-Bonnin, Raül, van Merendonk, Lisanne N., Vidal-Alabró, Anna, Montero, Nuria, Melilli, Edoardo, Meneghini, Maria, Manonelles, Anna, Cruzado, Josep M., Torras, Juan, Grinyó, Josep Maria, Bestard, Oriol, Lloberas, Nuria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010682/
https://www.ncbi.nlm.nih.gov/pubmed/33815118
http://dx.doi.org/10.3389/fphar.2021.636048
_version_ 1783673107224985600
author Fontova, Pere
Colom, Helena
Rigo-Bonnin, Raül
van Merendonk, Lisanne N.
Vidal-Alabró, Anna
Montero, Nuria
Melilli, Edoardo
Meneghini, Maria
Manonelles, Anna
Cruzado, Josep M.
Torras, Juan
Grinyó, Josep Maria
Bestard, Oriol
Lloberas, Nuria
author_facet Fontova, Pere
Colom, Helena
Rigo-Bonnin, Raül
van Merendonk, Lisanne N.
Vidal-Alabró, Anna
Montero, Nuria
Melilli, Edoardo
Meneghini, Maria
Manonelles, Anna
Cruzado, Josep M.
Torras, Juan
Grinyó, Josep Maria
Bestard, Oriol
Lloberas, Nuria
author_sort Fontova, Pere
collection PubMed
description Introduction: Tacrolimus is the backbone immunosuppressant after solid organ transplantation. Tacrolimus has a narrow therapeutic window with large intra- and inter-patient pharmacokinetic variability leading to frequent over- and under-immunosuppression. While routine therapeutic drug monitoring (TDM) remains the standard of care, tacrolimus pharmacokinetic variability may be influenced by circadian rhythms. Our aim was to analyze tacrolimus pharmacokinetic/pharmacodynamic profiles on circadian rhythms comparing morning and night doses of a twice-daily tacrolimus formulation. Methods: This is a post-hoc analysis from a clinical trial to study the area under curve (AUC) and the area under effect (AUE) profiles of calcineurin inhibition after tacrolimus administration in twenty-five renal transplant patients. Over a period of 24 h, an intensive sampling (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 15, 20, and 24 h) was carried out. Whole blood and intracellular tacrolimus concentrations and calcineurin activity were measured by UHPLC-MS/MS. Results: Whole blood and intracellular AUC(12–24 h) and C(max) achieved after tacrolimus night dose was significantly lower than after morning dose administration (AUC(0–12 h)) (p < 0.001 for both compartments). AUE(0–12 h) and AUE(12–24 h) were not statistically different after morning and night doses. Total tacrolimus daily exposure (AUC(0–24 h)), in whole blood and intracellular compartments, was over-estimated when assessed by doubling the morning AUC(0–12 h) data. Conclusion: The lower whole blood and intracellular tacrolimus concentrations after night dose might be influenced by a distinct circadian clock. This significantly lower tacrolimus exposure after night dose was not translated into a significant reduction of the pharmacodynamic effect. Our study may provide conceptual bases for better understanding the TDM of twice-daily tacrolimus formulation.
format Online
Article
Text
id pubmed-8010682
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80106822021-04-01 Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation Fontova, Pere Colom, Helena Rigo-Bonnin, Raül van Merendonk, Lisanne N. Vidal-Alabró, Anna Montero, Nuria Melilli, Edoardo Meneghini, Maria Manonelles, Anna Cruzado, Josep M. Torras, Juan Grinyó, Josep Maria Bestard, Oriol Lloberas, Nuria Front Pharmacol Pharmacology Introduction: Tacrolimus is the backbone immunosuppressant after solid organ transplantation. Tacrolimus has a narrow therapeutic window with large intra- and inter-patient pharmacokinetic variability leading to frequent over- and under-immunosuppression. While routine therapeutic drug monitoring (TDM) remains the standard of care, tacrolimus pharmacokinetic variability may be influenced by circadian rhythms. Our aim was to analyze tacrolimus pharmacokinetic/pharmacodynamic profiles on circadian rhythms comparing morning and night doses of a twice-daily tacrolimus formulation. Methods: This is a post-hoc analysis from a clinical trial to study the area under curve (AUC) and the area under effect (AUE) profiles of calcineurin inhibition after tacrolimus administration in twenty-five renal transplant patients. Over a period of 24 h, an intensive sampling (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 15, 20, and 24 h) was carried out. Whole blood and intracellular tacrolimus concentrations and calcineurin activity were measured by UHPLC-MS/MS. Results: Whole blood and intracellular AUC(12–24 h) and C(max) achieved after tacrolimus night dose was significantly lower than after morning dose administration (AUC(0–12 h)) (p < 0.001 for both compartments). AUE(0–12 h) and AUE(12–24 h) were not statistically different after morning and night doses. Total tacrolimus daily exposure (AUC(0–24 h)), in whole blood and intracellular compartments, was over-estimated when assessed by doubling the morning AUC(0–12 h) data. Conclusion: The lower whole blood and intracellular tacrolimus concentrations after night dose might be influenced by a distinct circadian clock. This significantly lower tacrolimus exposure after night dose was not translated into a significant reduction of the pharmacodynamic effect. Our study may provide conceptual bases for better understanding the TDM of twice-daily tacrolimus formulation. Frontiers Media S.A. 2021-03-17 /pmc/articles/PMC8010682/ /pubmed/33815118 http://dx.doi.org/10.3389/fphar.2021.636048 Text en Copyright © 2021 Fontova, Colom, Rigo-Bonnin, van Merendonk, Vidal-Alabró, Montero, Melilli, Meneghini, Manonelles, Cruzado, Torras, Grinyó, Bestard and Lloberas. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Fontova, Pere
Colom, Helena
Rigo-Bonnin, Raül
van Merendonk, Lisanne N.
Vidal-Alabró, Anna
Montero, Nuria
Melilli, Edoardo
Meneghini, Maria
Manonelles, Anna
Cruzado, Josep M.
Torras, Juan
Grinyó, Josep Maria
Bestard, Oriol
Lloberas, Nuria
Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation
title Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation
title_full Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation
title_fullStr Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation
title_full_unstemmed Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation
title_short Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation
title_sort influence of the circadian timing system on tacrolimus pharmacokinetics and pharmacodynamics after kidney transplantation
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010682/
https://www.ncbi.nlm.nih.gov/pubmed/33815118
http://dx.doi.org/10.3389/fphar.2021.636048
work_keys_str_mv AT fontovapere influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation
AT colomhelena influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation
AT rigobonninraul influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation
AT vanmerendonklisannen influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation
AT vidalalabroanna influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation
AT monteronuria influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation
AT melilliedoardo influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation
AT meneghinimaria influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation
AT manonellesanna influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation
AT cruzadojosepm influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation
AT torrasjuan influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation
AT grinyojosepmaria influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation
AT bestardoriol influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation
AT lloberasnuria influenceofthecircadiantimingsystemontacrolimuspharmacokineticsandpharmacodynamicsafterkidneytransplantation